How do we … integrate pathogen reduced platelets into our hospital blood bank inventory?

Transfusion

Volumn 59, Issue 5, 2019, Pages 1628-1636

  Rutter, Sara ^a   Snyder, Edward L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PSORALEN;

ARTICLE; BLOOD BANK; FINANCIAL MANAGEMENT; HEALTH CARE QUALITY; HEALTH SERVICE; HOSPITAL CARE; HUMAN; INFECTIOUS AGENT; INFORMATION TECHNOLOGY; MEDICAL ETHICS; MEDICOLEGAL ASPECT; NURSING STAFF; STAFF TRAINING; THROMBOCYTE; THROMBOCYTE TRANSFUSION; BLOOD SAFETY; BLOOD TRANSFUSION; BLOODBORNE BACTERIUM; DONOR SELECTION; PROCEDURES;

BLOOD BANKS; BLOOD PLATELETS; BLOOD SAFETY; BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; DONOR SELECTION; HUMANS;

EID: 85065121916     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.15241     Document Type: Article

References (47)

1. Cerus Corporation. FDA approves pathogen reduction system to treat platelets. [Press Release]. 2014. [accessed 2019 Mar 11] Available from: http://www.cerus.com/Investors/Press-Releases/Press-Release-Details/2014/FDA-Approves-INTERCEPT-Blood-System-for-Platelets/default.aspx
2. US Food and Drug Administration/Center for Biologics Evaluation and Research. Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion: draft guidance for industry. Silver Spring, MD; 2018. [accessed 2019 Mar 11] Available from: https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-bio-gen/documents/document/ucm627407.pdf
3. Lin L, Conlan MG, Tessman J, et al. Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment. Transfusion 2005;45:1610-20.
4. Mundt J, Rouse L, Van den Bossche J, et al. Chemical and biological mechanisms of pathogen reduction technologies. Photochem Photobiol 2014;90:957-64.
5. Ciaravino V, McCullough T, Dayan AD. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets. Hum Exp Toxicol 2001;20:533-50.
6. US Food and Drug Administration. Summary of safety and effectiveness data: INTERCEPT blood system for platelets. [Press Release]. 2014. [accessed 2019 Mar 11] Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/UCM431243.pdf
7. Cerus Corporation. INTERCEPT Blood System for Platelets [Package Insert]. Concord (CA); 2015.
8. Lam S, Tan HC, Tan LK, et al. Efficacy of INTERCEPT treatment for the inactivation of Dengue virus in single-donor platelet concentrate: SP266. Transfusion 2007;47:131A-2A.
9. Rentas F, Harman RW, Gomez C, et al. Inactivation of Orientia tsutsugamushi using INTERCEPT blood system for plasma, as demonstrated in an animal model. Transfusion 2004;44:104A.
10. Sampson-Johannes A, Sawyer L. Helinx® technology inactivates Vaccinia virus in human platelet concentrates. Transfusion 2003;43:83A.
11. Santa Maria F, Laughhunn A, Girard Y, et al. Simultaneous inactivation of co-circulating arboviruses through nucleic acid crosslinking. Transfusion 2018;58(S2):24A. [accessed 2019 Mar 11] Abstract retrieved from https://onlinelibrary.wiley.com/doi/10.1111/trf.14903, Abstract Presentations from the AABB Annual Meeting Boston, MA, October 13-16, 2018.
12. Rasongles P, Angelini-Tibert MF, Simon P, et al. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de la Reunion. Transfusion 2009;49:1083-91.
13. Pinna D, Sampson-Johannes A, Clementi M, et al. Amotosalen photochemical inactivation of severe acute respiratory syndrome coronavirus in human platelet concentrates. Transfusion 2005;15:269-76.
14. Grass JA, Hei DJ, Metchette K, et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998;91:2180-8.
15. Luban NL, Drothler D, Moroff G, et al. Irradiation of platelet components: inhibition of lymphocyte proliferation assessed by limiting-dilution analysis. Transfusion 2000;40:348-52.
16. Pelszynski MM, Moroff G, Luban NL, et al. Effect of gamma irradiation of red blood cell units on T-cell inactivation as assessed by limiting-dilution analysis: implications for preventing transfusion associated graft versus host disease. Blood 1994;83:1683-9.
17. Tran J, Jackman R. Pathogen reduction of platelet rich plasma abrogates T cell allo response in mice. Transfusion 2018;58(S2): 58A. [accessed 2019 Mar 11] Abstract retrieved from https://onlinelibrary.wiley.com/doi/10.1111/trf.14903, Abstract Presentations from the AABB Annual Meeting Boston, MA, October 13-16, 2018.
18. Setlow RB, Setlow JK. Effect of radiation on polynucleotides. In: Baldwin ML Jeffries LC, editors. Irradiation of blood components. Bethesda (MD): AABB; 1992. p. 1.
19. Knutson F, Osselaer J, Pierelli L, et al. A prospective, active haemovigilance study with combined cohort analysis of 19 175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang 2015;109:343-52 Swissmedic Haemovigilance Annual Report 2014.
20. Amato M, Schennach H, Astl M, et al. Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian regional medical center. Vox Sang 2017;112:47-55.
21. Nussbaumer W, Amato M, Schennach H, et al. Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients. Vox Sang 2017;112:249-56.
22. Amsler L, Jutzi M. Haemovigilance annual report 2014. Bern, Switzerland: Swissmedic; 2014.
23. Agence Nationale de Securite du Medicament et des Produits de Sante. Rapport d'activité hémovigilance 2013. France; 2014. [accessed 2019 Mar 11] Available from: https://ansm.sante.fr/var/ansm_site/storage/original/application/8a2c3c478172fcfbe027742aed130adf.pdf.
24. Cazenave JP, Waller C, Kientz D, et al. An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion 2010;50:1210-9.
25. Schlenke P. Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother 2014;41:309-25.
26. Seltam A. Pathogen inactivation of cellular blood products- an additional safety layer in transfusion medicine. Front Med 2017;4:219.
27. von Goetz M, North A, Muft N, et al. Assessment of safety in neonatal rates for transfusion of red blood cells prepared with the amustaline-Gsh pathogen reduction treatment. Transfusion 2018;58(S2):65A. [accessed 2019 Mar 11] Abstract retrieved from https://onlinelibrary.wiley.com/doi/10.1111/trf.14903, Abstract Presentations from the AABB Annual Meeting Boston, MA, October 13-16, 2018.
28. Graminske S, Dumont L, Anani WQ, et al. Transfer of the amustaline/Gsh pathogen reduction system to two US blood research centers. Transfusion 2018;58(S2):24A. [accessed 2019 Mar 11] Abstract retrieved from https://onlinelibrary.wiley.com/doi/10.1111/trf.14903, Abstract Presentations from the AABB Annual Meeting Boston, MA, October 13-16, 2018.
29. Prichard A, Kuhn M, Linares P, et al. Qualification of amustaline-GSH red blood cell pathogen reduction system for a phase 3 clinical trial. Transfusion 2018;58(S2):202A. [accessed 2019 Mar 11] Abstract retrieved from https://onlinelibrary.wiley.com/doi/10.1111/trf.14903, Abstract Presentations from the AABB Annual Meeting Boston, MA, October 13-16, 2018.
30. AABB/America's Blood Centers/American Red Cross. Re: docket no. FDA-2014-D-1814, “Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion” draft guidance, 15 March 2016. Bethesda, MD; 2017. [accessed 2019 Mar 11] Available from: http://www.aabb.org/advocacy/comments/Documents/comments170412.pdf
31. Nguyen J, Rioveros J, Ziman A, et al. Dual apheresis platelets inventory for a hospital-based donor center and transfusion service. Transfusion 2018;58(S2):26A. [accessed 2019 Mar 11] Abstract retrieved from https://onlinelibrary.wiley.com/doi/10.1111/trf.14903, Abstract Presentations from the AABB Annual Meeting Boston, MA, October 13-16, 2018.
32. Weiner E, Lummer M, Chrebtow V. Platelet availability and economic impact of bacterial risk reduction studies at US hospitals. Transfusion 2018;58(S2): 55A. [accessed 2019 Mar 11] Abstract retrieved from https://onlinelibrary.wiley.com/doi/10.1111/trf.14903, Abstract Presentations from the AABB Annual Meeting Boston, MA, October 13-16, 2018.
33. Corash L, Lin JS, Sherman CD, et al. Determination of acute lung injury after repeated platelet transfusions. Blood 2011;117:1014-20.
34. Amsler L, Jutzi M. Haemovigilance annual report 2016. Bern, Switzerland: Swissmedic; 2016.
35. Amsler L, Jutzi M. Haemovigilance annual report 2017. Bern, Switzerland: Swissmedic; 2017.
36. Corash BR. The role of hemovigilance and postmarketing studies when introducing innovation into transfusion medicine practice: the amotosalen-ultraviolet A pathogen reduction treatment model. Transfusion 2016;56:S29-38.
37. Schulz W, Gokhale A, McPadden J, et al. Blood utilization and transfusion reactions in pediatric patients transfused with conventional or pathogen reduced platelets. J Pediatr 2019 In press.
38. Gehrie E, Schulz W, Young P, et al. A retrospective evaluation of the hemostatic efficacy of pathogen reduced (PR) vs conventional (CONV) platelets at an academic medical center. Transfusion 2018;58(S2):104A. [accessed 2019 Mar 11] Abstract retrieved from https://onlinelibrary.wiley.com/doi/10.1111/trf.14903, Abstract Presentations from the AABB Annual Meeting Boston, MA, October 13-16, 2018.
39. Gokhale A, Schulz W, Bahar B, et al. Transfusion reaction rates of pathogen reduced (PR) vs conventional (CONV) platelets in adults: a single academic center experience. Transfusion 2018;58(S2):111A. [accessed 2019 Mar 11] Abstract retrieved from https://onlinelibrary.wiley.com/doi/10.1111/trf.14903, Abstract Presentations from the AABB Annual Meeting Boston, MA, October 13-16, 2018.
40. Gurevich I, Keener B, Kniep J. Activation status of pathogen reduced platelet components in plasma in comparison with conventional plasma platelet components. Transfusion 2018;58(S2):47A. [accessed 2019 Mar 11] Abstract retrieved from https://onlinelibrary.wiley.com/doi/10.1111/trf.14903, Abstract Presentations from the AABB Annual Meeting Boston, MA, October 13-16, 2018.
41. Garban F, Guyard A, Labussiere H, et al. Comparison of the Hemostatic efficacy of pathogen-reduced platelets vs untreated platelets in patients with thrombocytopenia and malignant hematologic diseases: a randomized clinical trial. JAMA Oncol 2018;4:468-75.
42. Jaquot C, Delaney M. Pathogen-inactivated blood products for pediatric patients: blood safety, patient safety, or both? Transfusion 2018;58:2095-101.
43. Stokowski LA. Fundamentals of phototherapy for neonatal jaundice. Adv Neonatal Care 2011;11:S10-21.
44. Vossoughi S, Perez G, Whitaker BI, et al. Analysis of pediatric adverse reactions to transfusions. Transfusion 2018;58:60-9.
45. Prioli K, Katz J, Lyons N, et al. Economic implications of pathogen reduced and bacterially tested platelet components: a US hospital budget impact model. Appl Health Econ Health Policy 2018;16:889-99.
46. McCullough J, Goldfinger D, Gorlin J, et al. Cost Implications of implementation of pathogen-inactivated platelets. Transfusion 2015;55:2312-20.
47. Kacker S, Bloch EM, Ness PM, et al. Financial impact of alternative approaches to reduce bacterial contamination of platelet transfusions. Transfusion 2019;59:1291-9.